Who and what is Phage Therapeutics?
Research and Development Focus!

For years, we have been researching the treatment of complex, multidrug-resistant Staphylococcus aureus (MRSA) infections and have successfully begun developing corresponding medications for the treatment of these infections.

To bring our research findings and the corresponding medications to market, Phage Therapeutics was founded by researchers and a global team of experienced managers in Switzerland and Germany, two of the most innovative countries in the pharmaceutical industry.

We invite you to join us and our work on the road to market launch. Primary threats to global public health include a global infection crisis caused by multidrug-resistant organisms (MDROs) – MRSA (WHO, NIH, CDC)

  • MRSA's resistance/multidrug resistance to additional antibiotics
  • Spread of drug-resistant tuberculosis (MDROTB, XDRTB, TDRTB), HIV/AIDS, and malaria
  • The spread of new forms of drug-resistant tuberculosis, especially Totally Drug-Resistant Tuberculosis (TDRTB), which are virtually untreatable
  • Spread of antibiotic-resistant Pseudomonas aeruginosa
  • The continuous emergence of new resistance mechanisms in various bacterial pathogens, resulting in over 55 million deaths worldwide each year (as of 2019):
  • 20 million – infectious diseases
  • 15 million – cardiovascular diseases
  • 6 million – cancer
  • 3 million – other respiratory diseases
  • 11 million – various other causes

Bacterial infectious diseases are the greatest

concern in USA and EU:

  • Methicillin-resistant Staphylococcus aureus (MRSA)
  • Drug-resistant TB (Mycobacterium tuberculosis:
    MDRTB, XDRTB, TDRTB
  • Clostridium difficile
  • Carbapenem-resistant Enterobacteriaceae (Klebsiella) spp. & E. coli)
  • Drug-resistant Neisseria gonorrhoeae
  • Multidrug-resistant Acinetobacter baumannii (MDRAB)
  • Multidrug-resistant Pseudomonas aeruginosa